Hoth Therapeutics Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>HT</div>
HOTH -- USA Stock  

USD 2.23  0.24  9.72%

While some traders are getting carried away by overanalyzing healthcare space, it is reasonable to concentrate on Hoth Therapeutics against current market trends. As expected, Hoth Therapeutics is starting to reaffirm its true potential as stockholders are becoming more and more confident in the future outlook. Much of the latest Hoth Therapeutics price drift was an exact opposite of how the market drifted in the last few months. Fragile basic indicators of the company may also hint to signs of long-run losses for Hoth Therapeutics stockholders. The stock goes through an active upward rally.
Published over three weeks ago
View all stories for Hoth Therapeutics | View All Stories
Is Hoth Therapeutics (NASDAQ:HOTH) a good mid run opportunity?
Hoth Therapeutics's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Hoth Therapeutics market sentiment investors' perception of the future value of Hoth Therapeutics. Let us look at a few aspects of Hoth Therapeutics technical analysis. About 38.0% of the company shares are held by company insiders. The book value of Hoth Therapeutics was currently reported as 0.4. The company recorded a loss per share of 0.9. Hoth Therapeutics had not issued any dividends in recent years.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Hoth Therapeutics. In general, we focus on analyzing Hoth Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Hoth Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Hoth Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Hoth Therapeutics, we also check how macroeconomic factors affect Hoth Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Hoth Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Hoth Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Hoth Therapeutics. Your research has to be compared to or analyzed against Hoth Therapeutics' peers to derive any actionable benefits. When done correctly, Hoth Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Hoth Therapeutics.

How does Hoth Therapeutics Stands against Peers?

Analyzing Hoth Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Hoth Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Hoth Therapeutics Competition Details

How Hoth Therapeutics utilizes its cash?

To perform a cash flow analysis of Hoth Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Hoth Therapeutics is receiving and how much cash it distributes out in a given period. The Hoth Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Hoth Therapeutics Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (4.45 Million)

Acquisition by Linsley Wayne of 15000 shares of Hoth Therapeutics subject to Rule 16b-3

Legal trades by Hoth Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Hoth Therapeutics insider trading alert for grant of options by Linsley Wayne, the corporate stakeholder, on 23rd of July 2020. This event was filed by Hoth Therapeutics Inc with SEC on 2020-07-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Hoth Therapeutics Indicators

This firm has a beta of -1.1935. Let's try to break down what Hoth Therapeutics's beta means in this case. The returns on MARKET and Hoth Therapeutics are completely uncorrelated. The beta indicator helps investors understand whether Hoth Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Hoth Therapeutics deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Net Loss for the year was (10.35 M).

Hoth Therapeutics implied volatility may change after the rise

Mean deviation is down to 4.72. It may hint to a possible volatility drop. Hoth Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Hoth Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Hoth Therapeutics volatility.

Our Takeaway on Hoth Therapeutics Investment

When is the right time to buy or sell Hoth Therapeutics? Buying stocks such as Hoth Therapeutics isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis. The inconsistency in the assessment between current Hoth Therapeutics valuation and our trade advice on Hoth Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Hoth Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Hoth Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com